Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?

Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet